Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $18 | $16 | $13 | $14 |
| % Growth | 13.1% | 22.2% | -5.9% | – |
| Cost of Goods Sold | $3 | $2 | $2 | $2 |
| Gross Profit | $15 | $13 | $11 | $11 |
| % Margin | 82.9% | 84.3% | 82.5% | 82.2% |
| R&D Expenses | $4 | $3 | $3 | $3 |
| G&A Expenses | $3 | $3 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $6 | $5 | $5 |
| Operating Income | $8 | $7 | $5 | $6 |
| % Margin | 43.9% | 45.8% | 42.5% | 42.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$2 | -$1 |
| Pre-Tax Income | $7 | $7 | $3 | $5 |
| Tax Expense | $2 | $1 | $1 | $1 |
| Net Income | $6 | $6 | $3 | $4 |
| % Margin | 31.7% | 36.4% | 21.7% | 32.6% |
| EPS | 6.22 | 6.3 | 3.07 | 4.91 |
| % Growth | -1.3% | 105.2% | -37.5% | – |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $8 | $8 | $4 | $6 |
| % Margin | 44.8% | 48.2% | 32.7% | 42.5% |